Martine A. Rothblatt, CEO of United Therapeutics Corp (NASDAQ:UTHR), Sells Over $1.1 Million Worth of Company Shares - SEC Filing Reveals
Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), recently sold a portion of her company shares, according to a recent SEC filing. The transactions, which occurred on July 31, 2024, involved the sale of shares at prices ranging from $313.05 to $323.8406, totaling over $1.1 million.
The sales were executed in multiple trades, with the highest price per share reaching $323.8406 and the lowest recorded at $313.05. Additionally, Rothblatt exercised options to acquire 3,600 shares of common stock at a price of $129.49 per share, totaling approximately $466,164. This exercise was part of a pre-arranged trading plan under Rule 10b5-1.
United Therapeutics Corp, a pharmaceutical company based in Silver Spring, Maryland, reported record revenue of $715 million for the second quarter of 2024, attributing the growth to the success of key products like Tyvaso. The company has conveyed an optimistic outlook for the future, focusing on the development of next-generation products and organ manufacturing.
Investors should pay attention to these transactions as they indicate movements within the company's leadership stock holdings. United Therapeutics' strong financial metrics and market performance, including a Market Cap of $14.58 billion USD and a Gross Profit Margin of 88.85%, suggest a company performing well and delivering value to shareholders.
Analyzing the company through InvestingPro metrics and tips reveals a solid financial position, with management engaging in share buybacks and holding more cash than debt. United Therapeutics' P/E Ratio of 14.11 and Gross Profit Margin of 88.85% indicate potential undervaluation and efficient operations, respectively. These insights can guide investors in making informed decisions about including United Therapeutics in their portfolio.
